Trial · NCT07912775
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in pain intensity (Visual Analogue Scale, VAS) after the acute phase | Baseline (T0) and after the acute phase at 1 week (T1) | Change from baseline in pain intensity measured with the Visual Analogue Scale (VAS), comparing active tDCS with sham tDCS. Scores range from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate a worse outcome. Responders are defined as participants with a reduction of at least 2 points from baseline. |
| Secondary | Change in pain intensity (Visual Analogue Scale, VAS) from the end of the acute phase through maintenance | From the end of the acute phase at 1 week (T1) to the end of maintenance at up to 2 months (T4) | Change in pain intensity measured with the Visual Analogue Scale (VAS), relative to baseline, from the end of the acute phase through the end of maintenance (assessed at T2, T3, and T4). Scores range from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate a worse outcome. |
| Secondary | Change in pain severity and interference (Brief Pain Inventory, BPI) | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in pain severity and pain interference with daily functioning measured with the Brief Pain Inventory - Short Form (BPI-SF). The severity score (mean of 4 items) and the interference score (mean of 7 items) each range from 0 to 10; higher scores indicate greater severity and interference (worse outcome). |
| Secondary | Change in anxiety and depression (Hospital Anxiety and Depression Scale, HADS) | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in anxiety and depression symptoms, measured with the 14-item Hospital Anxiety and Depression Scale (HADS). The anxiety and depression subscales each range from 0 to 21; higher scores indicate more severe symptoms (worse outcome). |
| Secondary | Change in global cognitive function (Montreal Cognitive Assessment, Spanish version, MoCA-S) | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in global cognitive function, measured with the Spanish version of the Montreal Cognitive Assessment (MoCA-S). Total scores range from 0 to 30; higher scores indicate better cognitive function (better outcome). |
| Secondary | Change in information processing speed (Symbol Digit Modalities Test, SDMT) | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in information processing speed and attention measured with the written Symbol Digit Modalities Test (SDMT), scored as the number of correct responses in 90 seconds. Scores range from 0 to 110; higher scores indicate better performance (better outcome). |
| Secondary | Change in sustained attention and working memory (Paced Auditory Serial Addition Test, PASAT-3) | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in sustained and divided attention and working memory measured with the 3-second version of the Paced Auditory Serial Addition Test (PASAT-3), scored as the number of correct responses. Scores range from 0 to 60; higher scores indicate better performance (better outcome). |
| Secondary | Change in verbal fluency (Controlled Oral Word Association Test, COWAT) | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in executive function and semantic and phonemic verbal fluency measured with the Controlled Oral Word Association Test (COWAT), scored as the total number of correct words generated (60 seconds per letter or category). The minimum score is 0 and there is no fixed maximum; higher scores indicate better performance (better outcome). |
| Secondary | Change in verbal learning and memory (Rey Auditory Verbal Learning Test, RAVLT) | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in verbal learning and short- and long-term auditory-verbal memory measured with the Rey Auditory Verbal Learning Test (RAVLT). Total learning across trials 1-5 ranges from 0 to 75; immediate (post-interference) and delayed recall each range from 0 to 15; higher scores indicate better performance (better outcome). |
| Secondary | Change in quality of life (World Health Organization Quality of Life - Brief Version, WHOQOL-BREF) | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in quality of life measured with the 26-item World Health Organization Quality of Life - Brief Version (WHOQOL-BREF). Physical, psychological, social relationships and environment domain scores are transformed to a 0-100 scale; higher scores indicate better quality of life (better outcome). |
| Secondary | Change in diurnal salivary cortisol | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in diurnal salivary cortisol, measured in saliva samples collected on two consecutive days and analyzed in duplicate by immunoassay. Mean values of the samples taken at the same time of day on both days are used. Concentrations are expressed in nmol/L. |
| Other | Number of participants with adverse events related to tDCS | From the first tDCS session to the end of participation (up to approximately 3 months) | Adverse events (e.g., tingling, stinging, itching, headache, skin redness) actively recorded during each stimulation session and at the scheduled visits, with severity, causality, and outcome documented. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07912775/registered